Mesoblast Limited
MEOBF
$1.35
-$0.62-31.30%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.02M | 7.02M | 1.58M | 1.58M | 1.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.02M | 7.02M | 1.58M | 1.58M | 1.26M |
| Cost of Revenue | 23.25M | 23.25M | -3.28M | -3.28M | 15.93M |
| Gross Profit | -16.23M | -16.23M | 4.86M | 4.86M | -14.68M |
| SG&A Expenses | 11.06M | 11.06M | 8.59M | 8.59M | 6.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 176.00K | 176.00K | 21.50K | 21.50K | 40.50K |
| Total Operating Expenses | 28.25M | 28.25M | 11.57M | 11.57M | 16.95M |
| Operating Income | -21.23M | -21.23M | -9.99M | -9.99M | -15.69M |
| Income Before Tax | -27.05M | -27.05M | -23.86M | -23.86M | -27.75M |
| Income Tax Expenses | 59.00K | 59.00K | 106.00K | 106.00K | -44.50K |
| Earnings from Continuing Operations | -27.10M | -27.10M | -23.97M | -23.97M | -27.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.10M | -27.10M | -23.97M | -23.97M | -27.71M |
| EBIT | -21.23M | -21.23M | -9.99M | -9.99M | -15.69M |
| EBITDA | -19.64M | -19.64M | -9.45M | -9.45M | -15.26M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.27B | 1.27B | 1.14B | 1.14B | 1.10B |
| Average Diluted Shares Outstanding | 1.27B | 1.27B | 1.14B | 1.14B | 1.10B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |